<p>你是否在尋找股價低廉的股票？雖然有成千上萬的股票每股交易價格低於 5 美元可供選擇，但要找到價格低廉的贏家可能會有些困難。畢竟，每股交易價格低於 5 美元的股票被視為低價股。如果你是投資者，你會知道低價股伴隨着增加的風險。</p>
<p>另一方面，如果你選擇正確，投資低價股可能會帶來豐厚的回報。</p>
<p>話雖如此，雖然我投資於各行各業，但我最喜歡關注的一些低價股是生物技術行業的股票。這些公司通常處於發展階段，這為可能推動它們股價上漲的幾個催化劑打開了大門。接下來，我們將討論為什麼低價股存在風險，以及我為什麼喜歡投資生物技術低價股。我還將分享四個每股交易價格低於 5 美元的生物技術股票，你應該考慮現在購買。</p>
<p><strong>要點</strong></p>
<ul>
<li>低於 5 美元的股票帶來額外風險，但可能帶來有意義的回報。</li>
<li>我喜歡生物技術低價股，因為它們往往伴隨着一長串可能推動股價上漲的催化劑。</li>
<li>MIST、RLYB、TSBX 和 LVTX 都是目前值得考慮的股票。</li>
<li>還有一隻股票你應該瞭解，可能會帶來類似英偉達的收益。閲讀報告。</li>
</ul>
<h2>為什麼低價股存在風險？</h2>
<p>低價股存在風險，因為它們通常代表着發展不足和無利潤的公司。這些公司通常依賴投資者提供資金來開發產品。如果資金枯竭或者他們開發的產品效果不佳，這些公司可能會倒閉，導致投資者損失。</p>
<h2>為什麼我喜歡生物技術低價股？</h2>
<p>生物技術低價股通常代表着生物技術公司處於發展階段。這些公司正在研究新的潛在治療方法或參與圍繞這些治療方法的臨牀試驗。對我來説，這是令人興奮的，因為這意味着可能會有幾個值得期待的催化劑。一些最重要的催化劑包括：</p>
<ul>
<li><strong>招募消息</strong>：生物技術公司必須招募患者參加臨牀試驗。代表這些公司的股票可能會在臨牀試驗招募完成後飆升。</li>
<li><strong>新數據</strong>：圍繞正在開發的生物技術產品的任何積極新數據可能推動股價上漲。</li>
<li><strong>申請提交</strong>：生物技術公司必須獲得 FDA 批准銷售他們開發的大部分產品。因此，FDA 的申請提交和接受可能導致收益。</li>
<li><strong>藥物批准</strong>：當生物技術低價股獲得新藥批准時，往往會看到戲劇性的增長。</li>
</ul>
<h2>4 只每股交易價格低於 5 美元的股票現在值得購買</h2>
<p>以下是四隻每股交易價格低於 5 美元的生物技術股票，可能值得加入你的投資組合：</p>
<h2>Milestone Pharmaceuticals</h2>
<p><img src="https://imageproxy.pbkrs.com/https://247wallst.com/wp-content/uploads/2015/10/thinkstockphotos-101538677.jpg?x-oss-process=image/auto-orient,1/interlace,1/resize,w_1440,h_1440/quality,q_95/format,jpg" alt="" width="1619" height="1619" original-src="https://imageproxy.pbkrs.com/https://247wallst.com/wp-content/uploads/2015/10/thinkstockphotos-101538677.jpg"/></p>
<p>Milestone Pharmaceuticals（納斯達克：MIST）是一家處於臨牀階段的生物技術公司。這意味着它有研究項目已經進入臨牀測試階段。該公司正在致力於開發兩種與心臟節律有關的治療方法。這些治療方法包括心房顫動和 PSTV。</p>
<p>在心房顫動方面，Milestone Pharmaceuticals 目前正在進行 2 期臨牀試驗。這些試驗的積極數據可能會推動股價飆升。但在我看來，還有更令人興奮的消息值得關注。</p>
<p>該公司宣佈 FDA 於 2024 年 5 月 29 日接受其 CARDAMYST 的新藥申請（NDA）。在接受後，FDA 將 PDUFA 日期（決定是否批准或拒絕藥物的日期）定為 2025 年 3 月 26 日，距離申請被接受 10 個月。</p>
<p>考慮到這一點，可能會有幾個催化劑。不僅公司 2 期臨牀試驗的積極數據可能帶來收益，任何與 CARDAMYST 潛在批准有關的消息（如委員會投票）都可能推動股價上漲。</p>
<p>分析師似乎對這種可能性感到興奮。目前有四位分析師對該股發表意見，其中一位給予買入評級，兩位給予表現優異評級，一位給予持有評級。中位數目標價為 7 美元，表明與目前每股低於 1.40 美元的價格相比，還有很大的增長空間。</p>
<h2>Rallybio 股票</h2>
<p><img src="https://imageproxy.pbkrs.com/https://247wallst.com/wp-content/uploads/2015/11/thinkstockphotos-474151326.jpg?x-oss-process=image/auto-orient,1/interlace,1/resize,w_1440,h_1440/quality,q_95/format,jpg" alt="" width="1416" height="1416" original-src="https://imageproxy.pbkrs.com/https://247wallst.com/wp-content/uploads/2015/11/thinkstockphotos-474151326.jpg"/></p>
<p>Rallybio（納斯達克：RLYB）是一家早期臨牀階段的生物技術公司。這意味着該公司正在進行早期臨牀試驗，這些試驗通常用作概念驗證試驗。那麼，為什麼 Rallybio 能夠進入這份值得立即購買的低價股名單？這與該公司及其投資者可能面臨的催化劑數量有關。</p>
<p>該公司目前有六個正在進行的研究項目，涉及血液疾病。這些疾病包括母胎出血疾病、補體失調、貧血和代謝性疾病。該公司的兩個研究項目已經進入 1 期臨牀試驗階段。這些項目包括 RLYB212 和 RLYB116。當然，這兩個臨牀試驗的任何積極數據都可能推動 Rallybio 股價上漲。</p>
<p>值得注意的是，該公司還有兩個處於臨牀前階段的項目——在將治療方法測試於人類之前進行進一步研究的階段。該公司還有兩個項目處於發現階段。</p>
<p>由於圍繞潛在治療方法的六個進行中項目，該公司在短期內發佈數據的可能性相對較高。由於這些數據有可能推動股價飆升，這隻股票值得密切關注。</p>
<p>分析師們對這支股票也持樂觀態度。其中三位將其評為買入，兩位評為表現優異，一位評為持有。中位數價格目標為 12 美元，這表明相較於目前接近 1.20 美元的股價，股票有顯著的增長潛力。</p>
<h2>Turnstone Biologics</h2>
<p><img src="https://imageproxy.pbkrs.com/https://247wallst.com/wp-content/uploads/2018/07/thinkstockphotos-601373580.jpg?x-oss-process=image/auto-orient,1/interlace,1/resize,w_1440,h_1440/quality,q_95/format,jpg" alt="" width="1366" height="768" original-src="https://imageproxy.pbkrs.com/https://247wallst.com/wp-content/uploads/2018/07/thinkstockphotos-601373580.jpg"/></p>
<p>Turnstone Biologics（納斯達克：TSBX）是一家早期臨牀階段的生物技術公司，主要專注於固體腫瘤的治療。這一點很重要，因為即使在近幾十年來腫瘤學領域取得了巨大進展，固體腫瘤癌症在晚期仍然有很高的死亡率。</p>
<p>該公司目前有四個研究項目，其中兩個處於第一階段臨牀試驗階段，另外兩個處於臨牀前開發階段。擁有四個正在進行中的項目，可能會迎來幾個催化劑。畢竟，圍繞公司候選藥物的任何積極數據都可能導致股票價值的顯著增長。</p>
<p>而增長正是分析師們預期看到的。目前有三位分析師對 TSBX 發表意見，其中一位將其評為買入，一位評為表現優異，一位評為持有。每股 12 美元的中位數價格目標表明，該股票在未來一年內可能上漲超過 400%。</p>
<h2>Lava Therapeutics</h2>
<p><img src="https://imageproxy.pbkrs.com/https://247wallst.com/wp-content/uploads/2018/01/dangerous-drugs-e1534767559507.jpg?x-oss-process=image/auto-orient,1/interlace,1/resize,w_1440,h_1440/quality,q_95/format,jpg" alt="" width="1366" height="768" original-src="https://imageproxy.pbkrs.com/https://247wallst.com/wp-content/uploads/2018/01/dangerous-drugs-e1534767559507.jpg"/></p>
<p>Lava Therapeutics（納斯達克：LVTX）是另一家早期臨牀階段的腫瘤學公司。與 Turnstone Biologics 類似，該公司正在開發設計精準聚焦於腫瘤活動的 T 細胞療法。</p>
<p>Lava Therapeutics 目前有五個正在進行中的臨牀和臨牀前研究項目。其中兩個項目，LAVA-1207 和 PF-08046052，正在進行第一階段臨牀試驗。值得一提的是，後者是與輝瑞合作的試驗，輝瑞是在潛在的固體腫瘤治療領域領先的製藥公司。除了這些項目，該公司還有專注於血液惡性腫瘤和三個未公開透露適應症的臨牀前項目。</p>
<p>與名單上任何公司一樣，與 Lava Therapeutics 研發治療藥物相關的任何積極消息都可能推動股價飆升。也許這就是為什麼分析師對 LVTX 持如此積極的看法。</p>
<p>目前有四位分析師對 LVTX 進行覆蓋。其中兩位將其評為買入，另外兩位評為表現優異。目前的中位數價格目標為 5.57 美元。考慮到每股 1.84 美元的當前價格，如果分析師們正確的話，股票在未來一年內可能會多次增長。</p>
<h2>“下一個英偉達” 可能改變你的生活</h2>
<p>如果你錯過了英偉達的歷史性增長，那麼從人工智能中獲得改變生活的利潤的機會並沒有結束。</p>
<p>2009 年首次預測了英偉達人工智能崛起的 24/7 華爾街分析師剛剛發佈了一份名為 “下一個英偉達” 的全新研究報告。</p>
<p>點擊這裏下載您的免費副本。</p>
<p>這篇文章最初發表在 24/7 華爾街。</p>

MIST

<p>4 家股價低於 5 美元的生物科技股，值得考慮投資。Milestone Pharmaceuticals 是一家處於臨牀階段的生物科技公司，其藥物在臨牀試驗和 FDA 批准方面具有潛在的催化劑。分析師對其前景持樂觀態度</p>

<p>Are you looking for stocks to buy with low price tags? While there are thousands of stocks that trade for under $5 per share to choose from, it can be difficult to find winners with low sticker prices. After all, stocks that trade for under $5 per share are considered penny stocks. And if you’re an investor, you know that penny stocks come with increased risk.</p>
<div class="lb-trans"><p>你是否在尋找股價低廉的股票？雖然有成千上萬的股票每股交易價格低於 5 美元可供選擇，但要找到價格低廉的贏家可能會有些困難。畢竟，每股交易價格低於 5 美元的股票被視為低價股。如果你是投資者，你會知道低價股伴隨着增加的風險。</p>
</div><p>On the other hand, penny stock investments can be fruitful if you make the right picks.</p>
<div class="lb-trans"><p>另一方面，如果你選擇正確，投資低價股可能會帶來豐厚的回報。</p>
</div><p>With that said, while I do invest in various industries, some of my favorite penny stocks to follow are in the biotechnology industry. These companies are usually in the development stages, which opens the door to several catalysts that could send their prices up. Below, we’ll talk about why penny stocks are risky and why I like investing in biotech penny stocks. I’ll also share four biotech picks trading under $5 per share that you should consider buying now.</p>
<div class="lb-trans"><p>話雖如此，雖然我投資於各行各業，但我最喜歡關注的一些低價股是生物技術行業的股票。這些公司通常處於發展階段，這為可能推動它們股價上漲的幾個催化劑打開了大門。接下來，我們將討論為什麼低價股存在風險，以及我為什麼喜歡投資生物技術低價股。我還將分享四個每股交易價格低於 5 美元的生物技術股票，你應該考慮現在購買。</p>
</div><p><strong>Key Points</strong></p>
<ul>
<li>Stocks under $5 come with added risk but can produce meaningful returns.</li>
<li>I enjoy biotech penny stocks, as they tend to come with a laundry list of catalysts that could send them higher.</li>
<li>MIST, RLYB, TSBX, and LVTX are all stocks that are worth considering right now.</li>
<li>There’s another stock pick you should know about that can produce NVIDIA-like gains. Read the report here.</li>
</ul>
<div class="lb-trans"><p><strong>要點</strong></p>
<ul>
<li>低於 5 美元的股票帶來額外風險，但可能帶來有意義的回報。</li>
<li>我喜歡生物技術低價股，因為它們往往伴隨着一長串可能推動股價上漲的催化劑。</li>
<li>MIST、RLYB、TSBX 和 LVTX 都是目前值得考慮的股票。</li>
<li>還有一隻股票你應該瞭解，可能會帶來類似英偉達的收益。閲讀報告。</li>
</ul>
</div><h2>Why Are Penny Stocks Risky?</h2>
<div class="lb-trans"><h2>為什麼低價股存在風險？</h2>
</div><p>Penny stocks are risky because they typically represent underdeveloped and unprofitable companies. These companies typically rely on investors to provide the funding they need to develop products. If that funding dries up or the products they develop don’t work well, these companies could fail, leading to losses for their investors.</p>
<div class="lb-trans"><p>低價股存在風險，因為它們通常代表着發展不足和無利潤的公司。這些公司通常依賴投資者提供資金來開發產品。如果資金枯竭或者他們開發的產品效果不佳，這些公司可能會倒閉，導致投資者損失。</p>
</div><h2>Why I Like Biotechnology Penny Stocks</h2>
<div class="lb-trans"><h2>為什麼我喜歡生物技術低價股？</h2>
</div><p>Biotechnology penny stocks typically represent biotechnology companies in the development phases. These companies are either researching new potential treatments or taking part in clinical trials surrounding those treatments. That’s exciting for me since that means there may be several catalysts to look forward to. Some of the most important catalysts to watch out for include:</p>
<ul>
<li><strong>Enrollment News</strong>: Biotechnology companies must enroll patients into clinical trials. The stocks that represent these companies may spike upon the completion of enrollment for a clinical trial.</li>
<li><strong>New Data</strong>: Any positive new data surrounding a biotechnology product in development could send the price of the stock up.</li>
<li><strong>Application Submissions</strong>: Biotechnology companies must receive FDA approval to sell the majority of the products they develop. As such, FDA application submissions and acceptance can lead to gains.</li>
<li><strong>Drug Approvals</strong>: Biotech penny stocks often see dramatic gains when they achieve new drug approvals.</li>
</ul>
<div class="lb-trans"><p>生物技術低價股通常代表着生物技術公司處於發展階段。這些公司正在研究新的潛在治療方法或參與圍繞這些治療方法的臨牀試驗。對我來説，這是令人興奮的，因為這意味着可能會有幾個值得期待的催化劑。一些最重要的催化劑包括：</p>
<ul>
<li><strong>招募消息</strong>：生物技術公司必須招募患者參加臨牀試驗。代表這些公司的股票可能會在臨牀試驗招募完成後飆升。</li>
<li><strong>新數據</strong>：圍繞正在開發的生物技術產品的任何積極新數據可能推動股價上漲。</li>
<li><strong>申請提交</strong>：生物技術公司必須獲得 FDA 批准銷售他們開發的大部分產品。因此，FDA 的申請提交和接受可能導致收益。</li>
<li><strong>藥物批准</strong>：當生物技術低價股獲得新藥批准時，往往會看到戲劇性的增長。</li>
</ul>
</div><h2>4 Stocks Under $5 to Buy Now</h2>
<div class="lb-trans"><h2>4 只每股交易價格低於 5 美元的股票現在值得購買</h2>
</div><p>Here are four biotechnology stocks trading under $5 that may be worth adding to your investment portfolio:</p>
<div class="lb-trans"><p>以下是四隻每股交易價格低於 5 美元的生物技術股票，可能值得加入你的投資組合：</p>
</div><h2>Milestone Pharmaceuticals</h2>
<div class="lb-trans"><h2>Milestone Pharmaceuticals</h2>
</div><p><img src="https://imageproxy.pbkrs.com/https://247wallst.com/wp-content/uploads/2015/10/thinkstockphotos-101538677.jpg" alt="" original-src="https://247wallst.com/wp-content/uploads/2015/10/thinkstockphotos-101538677.jpg"/></p>
<p>Milestone Pharmaceuticals (Nasdaq: MIST) is a clinical-stage biotechnology company. That means it has research programs that have made it to clinical testing. The company is working to develop treatments for two indications, both of which have to do with the rhythm of the heart. Those indications include atrial fibrillation and PSTV.</p>
<div class="lb-trans"><p>Milestone Pharmaceuticals（納斯達克：MIST）是一家處於臨牀階段的生物技術公司。這意味着它有研究項目已經進入臨牀測試階段。該公司正在致力於開發兩種與心臟節律有關的治療方法。這些治療方法包括心房顫動和 PSTV。</p>
</div><p>On the atrial fibrillation side of the coin, Milestone Pharmaceuticals is currently taking part in Phase 2 clinical trials. Positive data from those trials could send the stock on a run for the top. But in my opinion, there’s even more exciting news to watch for.</p>
<div class="lb-trans"><p>在心房顫動方面，Milestone Pharmaceuticals 目前正在進行 2 期臨牀試驗。這些試驗的積極數據可能會推動股價飆升。但在我看來，還有更令人興奮的消息值得關注。</p>
</div><p>The company announced that the FDA accepted its New Drug Application (NDA) for CARDAMYST on May 29, 2024. Upon acceptance, the FDA set the PDUFA date (the date by which it must decide whether to approve or deny the drug) to March 26, 2025, 10 months following the acceptance of the application.</p>
<div class="lb-trans"><p>該公司宣佈 FDA 於 2024 年 5 月 29 日接受其 CARDAMYST 的新藥申請（NDA）。在接受後，FDA 將 PDUFA 日期（決定是否批准或拒絕藥物的日期）定為 2025 年 3 月 26 日，距離申請被接受 10 個月。</p>
</div><p>With that in mind, several catalysts may be ahead. Not only could positive data from the company’s Phase 2 clinical trial lead to gains, but any news (like a committee vote) having to do with the potential approval of CARDAMYST could send the stock up.</p>
<div class="lb-trans"><p>考慮到這一點，可能會有幾個催化劑。不僅公司 2 期臨牀試驗的積極數據可能帶來收益，任何與 CARDAMYST 潛在批准有關的消息（如委員會投票）都可能推動股價上漲。</p>
</div><p>Analysts seem to be excited about that possibility. Four analysts are currently weighing in on the stock, one who rates it a Buy, two who rate it an Outperform, and one who rates it a Hold. The median price target is $7, suggesting that there’s plenty of room for growth from the current price of under $1.40 per share.</p>
<div class="lb-trans"><p>分析師似乎對這種可能性感到興奮。目前有四位分析師對該股發表意見，其中一位給予買入評級，兩位給予表現優異評級，一位給予持有評級。中位數目標價為 7 美元，表明與目前每股低於 1.40 美元的價格相比，還有很大的增長空間。</p>
</div><h2>Rallybio Stock</h2>
<div class="lb-trans"><h2>Rallybio 股票</h2>
</div><p><img src="https://imageproxy.pbkrs.com/https://247wallst.com/wp-content/uploads/2015/11/thinkstockphotos-474151326.jpg" alt="" original-src="https://247wallst.com/wp-content/uploads/2015/11/thinkstockphotos-474151326.jpg"/></p>
<p>Rallybio (Nasdaq: RLYB) is an early clinical-stage biotechnology company. That means the company is working on early clinical trials which are generally used as proof-of-concept trials. So, why did Rallybio make it to this list of stocks under $5 to buy right now? It has to do with the number of catalysts that could be ahead for the company and its investors.</p>
<div class="lb-trans"><p>Rallybio（納斯達克：RLYB）是一家早期臨牀階段的生物技術公司。這意味着該公司正在進行早期臨牀試驗，這些試驗通常用作概念驗證試驗。那麼，為什麼 Rallybio 能夠進入這份值得立即購買的低價股名單？這與該公司及其投資者可能面臨的催化劑數量有關。</p>
</div><p>The company currently has six ongoing research programs addressing blood disorders. Those disorders include maternal-fetal bleed disorders, complement dysregulation, anemia, and metabolic disorders. Two of the company’s research programs have already made it to Phase 1 clinical trials. Those include RLYB212 and RLYB116. Of course, any positive data from these two clinical trials could send Rallybio shares up.</p>
<div class="lb-trans"><p>該公司目前有六個正在進行的研究項目，涉及血液疾病。這些疾病包括母胎出血疾病、補體失調、貧血和代謝性疾病。該公司的兩個研究項目已經進入 1 期臨牀試驗階段。這些項目包括 RLYB212 和 RLYB116。當然，這兩個臨牀試驗的任何積極數據都可能推動 Rallybio 股價上漲。</p>
</div><p>It’s also worth noting that the company has two programs in the preclinical phases — the phases in which further research is done before testing the treatments on humans. The company also has two programs in the discovery phases.</p>
<div class="lb-trans"><p>值得注意的是，該公司還有兩個處於臨牀前階段的項目——在將治療方法測試於人類之前進行進一步研究的階段。該公司還有兩個項目處於發現階段。</p>
</div><p>With six ongoing programs surrounding potential therapeutics, the likelihood that the company will release data in the near term is relatively high. Since that data has the potential to send the stock on a run for the top, this stock is well worth watching.</p>
<div class="lb-trans"><p>由於圍繞潛在治療方法的六個進行中項目，該公司在短期內發佈數據的可能性相對較高。由於這些數據有可能推動股價飆升，這隻股票值得密切關注。</p>
</div><p>Analysts are also bullish on the stock. Three of them rate the stock a Buy, two rate it an Outperform, and one rates it a Hold. The median price target is $12, pointing to significant potential growth over the current stock price that’s just shy of $1.20.</p>
<div class="lb-trans"><p>分析師們對這支股票也持樂觀態度。其中三位將其評為買入，兩位評為表現優異，一位評為持有。中位數價格目標為 12 美元，這表明相較於目前接近 1.20 美元的股價，股票有顯著的增長潛力。</p>
</div><h2>Turnstone Biologics</h2>
<div class="lb-trans"><h2>Turnstone Biologics</h2>
</div><p><img src="https://imageproxy.pbkrs.com/https://247wallst.com/wp-content/uploads/2018/07/thinkstockphotos-601373580.jpg" alt="" original-src="https://247wallst.com/wp-content/uploads/2018/07/thinkstockphotos-601373580.jpg"/></p>
<p>Turnstone Biologics (Nasdaq: TSBX) is an early clinical-stage biotech company with a central focus on the treatment of solid tumors. That’s important because solid tumor cancers typically have high mortality rates in late stages, even with the vast advancements that have been made in the field of oncology in recent decades.</p>
<div class="lb-trans"><p>Turnstone Biologics（納斯達克：TSBX）是一家早期臨牀階段的生物技術公司，主要專注於固體腫瘤的治療。這一點很重要，因為即使在近幾十年來腫瘤學領域取得了巨大進展，固體腫瘤癌症在晚期仍然有很高的死亡率。</p>
</div><p>The company currently has four research programs, two of which are in Phase 1 clinical trials and two of which are in preclinical development phases. With four ongoing programs, several catalysts could be ahead. After all, any positive data surrounding the company’s candidates could lead to significant gains in the value of the stock.</p>
<div class="lb-trans"><p>該公司目前有四個研究項目，其中兩個處於第一階段臨牀試驗階段，另外兩個處於臨牀前開發階段。擁有四個正在進行中的項目，可能會迎來幾個催化劑。畢竟，圍繞公司候選藥物的任何積極數據都可能導致股票價值的顯著增長。</p>
</div><p>And growth is exactly what analysts are expecting to see. Three analysts are currently weighing in on TSBX, one of whom rates the stock a Buy, one who rates it an Outperform, and one who rates it a Hold. The median price target of $12 per share suggests that the stock could climb more than 400% in the next year.</p>
<div class="lb-trans"><p>而增長正是分析師們預期看到的。目前有三位分析師對 TSBX 發表意見，其中一位將其評為買入，一位評為表現優異，一位評為持有。每股 12 美元的中位數價格目標表明，該股票在未來一年內可能上漲超過 400%。</p>
</div><h2>Lava Therapeutics</h2>
<div class="lb-trans"><h2>Lava Therapeutics</h2>
</div><p><img src="https://imageproxy.pbkrs.com/https://247wallst.com/wp-content/uploads/2018/01/dangerous-drugs-e1534767559507.jpg" alt="" original-src="https://247wallst.com/wp-content/uploads/2018/01/dangerous-drugs-e1534767559507.jpg"/></p>
<p>Lava Therapeutics (Nasdaq: LVTX) is another early clinical-stage oncology company. Like Turnstone Biologics, the company is developing T-cell therapies that are designed to precisely focus on tumor activity.</p>
<div class="lb-trans"><p>Lava Therapeutics（納斯達克：LVTX）是另一家早期臨牀階段的腫瘤學公司。與 Turnstone Biologics 類似，該公司正在開發設計精準聚焦於腫瘤活動的 T 細胞療法。</p>
</div><p>Lava Therapeutics currently has five ongoing clinical and preclinical research programs. Two of those programs, LAVA-1207 and PF-08046052, are in Phase 1 clinical trials. It’s also worth noting that the latter is a trial in partnership with Pfizer, the leading pharmaceutical company in the potential treatment of solid tumors. Outside of these programs, the company has preclinical programs focused on hematological malignancies and three undisclosed indications.</p>
<div class="lb-trans"><p>Lava Therapeutics 目前有五個正在進行中的臨牀和臨牀前研究項目。其中兩個項目，LAVA-1207 和 PF-08046052，正在進行第一階段臨牀試驗。值得一提的是，後者是與輝瑞合作的試驗，輝瑞是在潛在的固體腫瘤治療領域領先的製藥公司。除了這些項目，該公司還有專注於血液惡性腫瘤和三個未公開透露適應症的臨牀前項目。</p>
</div><p>As is the case with any company on this list, any positive news having to do with Lava Therapeutics research and development therapeutics could send the stock to the top. Perhaps that’s why analysts have such a positive opinion of LVTX.</p>
<div class="lb-trans"><p>與名單上任何公司一樣，與 Lava Therapeutics 研發治療藥物相關的任何積極消息都可能推動股價飆升。也許這就是為什麼分析師對 LVTX 持如此積極的看法。</p>
</div><p>Four analysts currently cover LVTX. Two of them rate it a Buy, while the other two rate it an Outperform. The median price target is currently $5.57. Considering the current price of $1.84 per share, the stock could gain in multiples over the next year if analysts are correct.</p>
<div class="lb-trans"><p>目前有四位分析師對 LVTX 進行覆蓋。其中兩位將其評為買入，另外兩位評為表現優異。目前的中位數價格目標為 5.57 美元。考慮到每股 1.84 美元的當前價格，如果分析師們正確的話，股票在未來一年內可能會多次增長。</p>
</div><h2>“The Next NVIDIA” Could Change Your Life</h2>
<div class="lb-trans"><h2>“下一個英偉達” 可能改變你的生活</h2>
</div><p>If you missed out on NVIDIA’s historic run, your chance to see life-changing profits from AI isn’t over.</p>
<div class="lb-trans"><p>如果你錯過了英偉達的歷史性增長，那麼從人工智能中獲得改變生活的利潤的機會並沒有結束。</p>
</div><p>The 24/7 Wall Street Analyst who first called NVIDIA’s AI-fueled rise in 2009 just published a brand-new research report named “The Next NVIDIA.”</p>
<div class="lb-trans"><p>2009 年首次預測了英偉達人工智能崛起的 24/7 華爾街分析師剛剛發佈了一份名為 “下一個英偉達” 的全新研究報告。</p>
</div><p>Click here to download your FREE copy.</p>
<div class="lb-trans"><p>點擊這裏下載您的免費副本。</p>
</div><p>The post 4 Stocks Under $5 To Buy Now appeared first on 24/7 Wall St..</p>
<div class="lb-trans"><p>這篇文章最初發表在 24/7 華爾街。</p>
</div>

現在可以買入的 4 只 5 美元以下的股票